Covid-19: What now for remdesivir?

@article{Hsu2020Covid19WN,
  title={Covid-19: What now for remdesivir?},
  author={Jeremy Hsu},
  journal={BMJ},
  year={2020},
  volume={371}
}
  • J. Hsu
  • Published 19 November 2020
  • Medicine
  • BMJ
The spectre of past pandemics looms large over remdesivir, one of the first drug treatments for covid-19. With a WHO trial finding little benefit, Jeremy Hsu asks if the expensive drug is just Tamiflu redux? 

Major Update: Remdesivir for Adults With COVID-19

This first update of a living rapid review used to inform American College of Physicians Practice Points includes information from a newly published large multinational randomized controlled trial (RCT) as well as the final results of an RCT previously published as a preliminary report.

Covid-19: UK launches antivirals taskforce to deliver home treatments by autumn

Can the UK vaccine taskforce’s success in delivering safe and effective covid vaccines be repeated with new antiviral drugs? Elisabeth Mahase looks at the research pipeline

Covid-19: The lost lessons of Tamiflu

The history of the covid-19 pandemic will be strewn not only with lost lives and livelihoods but with the bloated carcasses of treatments hyped and bought at great expense, only to be found wanting.

The search for antivirals for covid-19

Antivirals are one of the most sought after, yet missing, tools to control SARS-COV-2. Chris Stokel-Walker asks what was learnt from a similar search nearly 20 years ago

Future developments in the prevention, diagnosis and treatment of COVID-19

Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability

This review covers the failure of some repurposed drugs that showed promising activity in the earlier CoV-pandemic but were found ineffective against SARS-CoV-2.

Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer?

The pros and cons of the vaccine rollout are discussed, the idea of a COVID medicinal toolbox made up of different antiviral treatment modalities is promoted, and some of the latest therapeutic strategies that are being explored to try to combat the COVID‐19 virus and other COVID viruses that are predicted to follow are presented.

Successful treatment of a South African cat with effusive feline infectious peritonitis with remdesivir.

  • M. Bohm
  • Medicine
    Journal of the South African Veterinary Association
  • 2022
The successful resolution of immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir at 4.9-5.6 mg/kg daily for 80 days is reported on.

The global governance of pandemics

The recent history of efforts to cope with crossborder health threats that set the stage for responses to the current pandemic are considered, and the record of international cooperation in the face of COVID19 is reviewed.

Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial

The use of remdesivir for the treatment of hospitalised patients with COVID-19 was not associated with clinical improvement at day 15 or day 29, nor with a reduction in mortality, nor in SARS-CoV-2 RNA.

References

SHOWING 1-10 OF 33 REFERENCES

Efficacy of Remdesivir in COVID-19.

The coronavirus disease 2019 (COVID-19) pandemic has strained health care systems across the globe, necessitating drastic public health measures and prompting a series of measures to protect against future pandemics.

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

The largest trial to date of treatments repurposed for use in the covid-19 pandemic has shown that none of the four drugs studied produced any measurable benefit in mortality or disease course. This

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

An overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness is provided.

The journey of remdesivir: from Ebola to COVID-19

Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated.

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment

It is argued that GS-441524 is superior to remdesivir for Covid-19 treatment because of its synthetic simplicity and in vivo efficacy in the veterinary setting.

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.

The Tamiflu fiasco and lessons learnt

This article takes a comprehensive relook on the Tamiflu saga, and suggests some ways and means to avoid a similar situation in the future.

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.

Institute for Clinical and Economic Review

Changes include separation of budget impact analysis from value determinations, introduction of other value measures beyond the QALY, increasing consideration of contextual elements, and adoption of a “societal perspective” where data support it.